Status:

COMPLETED

Study to Assess Safety and Effectiveness of Slowly Increasing Dose and Food Effect of KarXT in Participants With Schizophrenia

Lead Sponsor:

Karuna Therapeutics

Conditions:

Schizophrenia

Eligibility:

All Genders

18-65 years

Phase:

PHASE3

Brief Summary

The purpose of this study is to assess the safety and efficacy of slowly increasing dose and food effect of KarXT in adult participants with schizophrenia.

Eligibility Criteria

Inclusion

  • Has a primary diagnosis of schizophrenia established by a comprehensive psychiatric evaluation based on the DSM-5 (American Psychiatric Association 2013) criteria and confirmed by Mini International Neuropsychiatric Interview (MINI) for Schizophrenia and Psychotic Disorder Studies version 7.0.2.
  • Positive and Negative Syndrome Scale (PANSS) total score of ≤ 80 at screening and Baseline.
  • Clinical Global Impression-Severity (CGI-S) score of ≤ 4 at screening and Baseline.
  • Willing and able to discontinue all antipsychotic medications prior to baseline visit.

Exclusion

  • History or presence of clinically significant cardiovascular, pulmonary, renal, hematologic, gastrointestinal (GI), endocrine, immunologic, dermatologic, neurologic, or oncologic disease or any other condition that, in the opinion of the investigator, would jeopardize the safety of the participant or the validity of the study results.
  • Any primary DSM-5 disorder other than schizophrenia within 12 months before screening.
  • History of treatment resistance to schizophrenia medications.
  • History of allergy/hypersensitivity to KarXT.
  • Other protocol-defined Inclusion/Exclusion criteria apply.

Key Trial Info

Start Date :

October 28 2024

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

March 13 2025

Estimated Enrollment :

173 Patients enrolled

Trial Details

Trial ID

NCT06572449

Start Date

October 28 2024

End Date

March 13 2025

Last Update

April 2 2025

Active Locations (6)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 2 (6 locations)

1

Local Institution - 0002

Los Alamitos, California, United States, 90720-3118

2

Local Institution - 0004

Riverside, California, United States, 92506-3257

3

Local Institution - 0006

Hollywood, Florida, United States, 33024

4

Local Institution - 0005

Atlanta, Georgia, United States, 30331

Study to Assess Safety and Effectiveness of Slowly Increasing Dose and Food Effect of KarXT in Participants With Schizophrenia | DecenTrialz